REGENXBIO Inc. (NASDAQ:RGNX) Stock Holdings Raised by DnB Asset Management AS

DnB Asset Management AS grew its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 20.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,539 shares of the biotechnology company’s stock after purchasing an additional 2,434 shares during the quarter. DnB Asset Management AS’s holdings in REGENXBIO were worth $112,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. GAMMA Investing LLC raised its stake in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 2,510 shares in the last quarter. FMR LLC raised its position in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,656 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of REGENXBIO during the 4th quarter valued at approximately $54,000. EntryPoint Capital LLC bought a new position in REGENXBIO during the fourth quarter worth $97,000. Finally, Teacher Retirement System of Texas increased its stake in REGENXBIO by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 2,088 shares during the last quarter. Institutional investors own 88.08% of the company’s stock.

Wall Street Analysts Forecast Growth

RGNX has been the topic of a number of recent research reports. The Goldman Sachs Group downgraded shares of REGENXBIO from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $38.00 to $14.00 in a research report on Tuesday, February 11th. Chardan Capital reissued a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a report on Thursday, March 20th. Leerink Partners set a $24.00 target price on REGENXBIO in a research note on Tuesday, March 18th. HC Wainwright dropped their price target on REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Monday, March 17th. Finally, Morgan Stanley boosted their price objective on REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, March 14th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, REGENXBIO has an average rating of “Moderate Buy” and an average target price of $32.78.

REGENXBIO Trading Up 4.3 %

Shares of NASDAQ RGNX opened at $7.05 on Thursday. REGENXBIO Inc. has a 12-month low of $5.62 and a 12-month high of $20.77. The company has a market cap of $353.11 million, a PE ratio of -1.40 and a beta of 1.26. The stock has a 50 day simple moving average of $7.36 and a 200-day simple moving average of $8.65.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The company had revenue of $21.21 million during the quarter, compared to analysts’ expectations of $23.70 million. Sell-side analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.